Business Segments · Acquired in-process research and development
Reportable Segment — Acquired in-process research and development
Eli Lilly Reportable Segment — Acquired in-process research and development increased by 10.4% to $584.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 62.8%, from $1.57B to $584.00M. Over 3 years (FY 2022 to FY 2025), Reportable Segment — Acquired in-process research and development shows an upward trend with a 47.4% CAGR.
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityVolatile
First reportedQ1 2022
Last reportedQ1 2026Apr 30, 2026
Rolls up toAcquired in-process research and development
How to read this metric
Higher levels indicate a robust strategy for pipeline expansion through M&A, though it carries higher execution risk.
Detailed definition
Reflects the costs associated with acquiring intellectual property or research projects from third parties that have not...
Peer comparison
Comparable to IPR&D charges or business development expenses in the biotech and pharma industry.
Metric ID:
lly_segment_reportable_segment_acquired_in_process_research_and_developmentHistorical Data
17 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $227.13M | $227.13M | $227.13M | $227.13M | $950.00M | $950.00M | $950.00M | $950.00M | $110.50M | $154.30M | $2.83B | $188.80M | $1.57B | $153.80M | $655.70M | $528.80M | $584.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +318.3% | +0.0% | +0.0% | +0.0% | -88.4% | +39.6% | >999% | -93.3% | +732.6% | -90.2% | +326.3% | -19.4% | +10.4% |
| YoY Change | — | — | — | — | +318.3% | +318.3% | +318.3% | +318.3% | -88.4% | -83.8% | +197.5% | -80.1% | >999% | -0.3% | -76.8% | +180.1% | -62.8% |
Range$110.50M – $2.83B
CAGR+26.6%
Avg YoY Growth+198.5%
Median YoY Growth+180.1%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's reportable segment — acquired in-process research and development?
- Eli Lilly (LLY) reported reportable segment — acquired in-process research and development of $584.00M in Q1 2026.
- How has Eli Lilly's reportable segment — acquired in-process research and development changed year-over-year?
- Eli Lilly's reportable segment — acquired in-process research and development decreased by 62.8% year-over-year, from $1.57B to $584.00M.
- What is the long-term trend for Eli Lilly's reportable segment — acquired in-process research and development?
- Over 3 years (2022 to 2025), Eli Lilly's reportable segment — acquired in-process research and development has grown at a 47.4% compound annual growth rate (CAGR), from $908.50M to $2.91B.
- What does reportable segment — acquired in-process research and development mean?
- Costs incurred to purchase external research and development projects that are still in progress.